{"id":"W2763417272","doi":"10.1093/annonc/mdx369.157","title":"KEYNOTE-240: Phase 3, randomized study of pembrolizumab (pembro) vs best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Sorafenib; Medicine; Pembrolizumab; Internal medicine; Adverse effect; Placebo; Hepatocellular carcinoma; Response Evaluation Criteria in Solid Tumors; Oncology; Clinical trial; Surgery; Phases of clinical research; Cancer; Immunotherapy; Pathology; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001630045,0.001695856,0.002317437,0.0003945807,0.0004211086,0.001528017,0.001118681,0.001485295,0.01119428],"category_scores_gemma":[0.001443069,0.0007300545,0.002179067,0.000347167,0.001050734,0.001381424,0.0004548853,0.004545551,0.001968852],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009143488,"about_ca_system_score_gemma":0.001181156,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001196306,"about_ca_topic_score_gemma":0.002673811,"domain_scores_codex":[0.9996234,0.0001793057,0.00001813995,0.0000734479,0.00002759778,0.00007804557],"domain_scores_gemma":[0.9993192,0.0001759606,0.0001204692,0.00006183764,0.0000337902,0.0002887966],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9679527,0.0065823,0.0003925492,0.000708586,0.001227095,0.00003533339,0.00005102867,0.000546937,0.00374837,0.0001892735,0.001714675,0.01685117],"study_design_scores_gemma":[0.9594405,0.03783169,0.0007335393,0.00002451184,0.0004066604,0.00002972701,0.00001978115,0.0003215187,0.0003699237,0.0001908566,0.0006183269,0.00001294831],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.979095,0.005163021,0.001131516,0.001355342,0.001030275,0.004364392,0.002882037,0.0003517279,0.004626712],"genre_scores_gemma":[0.9781989,0.002973579,0.002656575,0.002438617,0.0005396794,0.004602024,0.002175764,0.00009199076,0.006322918],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01119428,"threshold_uncertainty_score":0.03744864,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09005920300160238,"score_gpt":0.425640743886083,"score_spread":0.3355815408844807,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}